SCHEMBL4852048

SCHEMBL4852048

CCOP(=O)(CCc1cn(-c2ccccc2)nc1OCc1ccc(OCc2nc(-c3ccco3)oc2C)c(OC)c1)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 6/20 0.47
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
MAPT P10636 4/20 0.41
TSHR P16473 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 4/20 0.37
USP2 O75604 2/20 0.37
MAPK1 P28482 2/20 0.37
ALOX15 P16050 2/20 0.37
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
PPARA Q07869 5/20 0.35
LCLAT1 Q6UWP7 1/20 0.33
RECQL P46063 1/20 0.33
APP P05067 1/20 0.33
ADORA3 P0DMS8 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848075 0.88 PPARG (0.50) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4853517 0.88 PPARG (0.49) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL5403506 0.87 PPARG (0.48) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL5407835 0.87 PPARG (0.50) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4851583 0.87 PPARG (0.50) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4850383 0.86 PPARG (0.48) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4849091 0.86 PPARG (0.49) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4844111 0.85 PPARG (0.48) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4848114 0.84 PPARG (0.48) PPARGKDM4ESMN1; SMN2MAPTTSHR
SCHEMBL4850485 0.83 PPARG (0.46) PPARGKDM4ESMN1; SMN2MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PPARG 536/4885KDM4E 719/4885SMN1; SMN2 4339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.